Article in Regenerative biomaterials, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
14 authors.
Álvaro Sierra-SánchezAndalusian Network of Design and Translation of Advanced Therapies, Unidad de Producción Celular e Ingeniería Tisular, Virgen de las Nieves University Hospital, Granada, 18014, Spain.ORCID https://orcid.org/0000-0003-4511-408X
Jorge Cabañas-PenagosAndalusian Network of Design and Translation of Advanced Therapies, Unidad de Producción Celular e Ingeniería Tisular, Virgen de las Nieves University Hospital, Granada, 18014, Spain.ORCID https://orcid.org/0009-0008-9793-0680
Sandra Igual-RogerAndalusian Network of Design and Translation of Advanced Therapies, Unidad de Producción Celular e Ingeniería Tisular, Virgen de las Nieves University Hospital, Granada, 18014, Spain.ORCID https://orcid.org/0000-0001-7336-3986
Luis Martínez-HerediaAndalusian Network of Design and Translation of Advanced Therapies, Unidad de Producción Celular e Ingeniería Tisular, Virgen de las Nieves University Hospital, Granada, 18014, Spain.ORCID https://orcid.org/0000-0001-9330-8108
Olga Espinosa-IbáñezAndalusian Network of Design and Translation of Advanced Therapies, Unidad de Producción Celular e Ingeniería Tisular, Virgen de las Nieves University Hospital, Granada, 18014, Spain.ORCID https://orcid.org/0000-0001-5757-7933
Raquel Sanabria-de la TorreAndalusian Network of Design and Translation of Advanced Therapies, Unidad de Producción Celular e Ingeniería Tisular, Virgen de las Nieves University Hospital, Granada, 18014, Spain.ORCID https://orcid.org/0000-0002-3261-6745
María I Quiñones-VicoAndalusian Network of Design and Translation of Advanced Therapies, Unidad de Producción Celular e Ingeniería Tisular, Virgen de las Nieves University Hospital, Granada, 18014, Spain.ORCID https://orcid.org/0000-0002-4984-1017
Ana Ubago-RodríguezAndalusian Network of Design and Translation of Advanced Therapies, Unidad de Producción Celular e Ingeniería Tisular, Virgen de las Nieves University Hospital, Granada, 18014, Spain.ORCID https://orcid.org/0000-0003-1311-8035
Antonio Lizana-MorenoAndalusian Network of Design and Translation of Advanced Therapies, Unidad de Producción Celular e Ingeniería Tisular, Virgen de las Nieves University Hospital, Granada, 18014, Spain.ORCID https://orcid.org/0000-0003-2647-5613
Ana Fernández-GonzálezAndalusian Network of Design and Translation of Advanced Therapies, Unidad de Producción Celular e Ingeniería Tisular, Virgen de las Nieves University Hospital, Granada, 18014, Spain.ORCID https://orcid.org/0000-0001-6852-0836
Jorge Guerrero-CalvoAndalusian Network of Design and Translation of Advanced Therapies, Unidad de Producción Celular e Ingeniería Tisular, Virgen de las Nieves University Hospital, Granada, 18014, Spain.ORCID https://orcid.org/0000-0003-1084-4509
Natividad Fernández-PorcelAndalusian Network of Design and Translation of Advanced Therapies, Unidad de Producción Celular e Ingeniería Tisular, Virgen de las Nieves University Hospital, Granada, 18014, Spain.ORCID https://orcid.org/0000-0003-3927-5717
Arena Ramírez-MuñozAndalusian Network of Design and Translation of Advanced Therapies, Unidad de Producción Celular e Ingeniería Tisular, Virgen de las Nieves University Hospital, Granada, 18014, Spain.ORCID https://orcid.org/0009-0006-5150-4614
Salvador Arias-SantiagoAndalusian Network of Design and Translation of Advanced Therapies, Unidad de Producción Celular e Ingeniería Tisular, Virgen de las Nieves University Hospital, Granada, 18014, Spain.ORCID https://orcid.org/0000-0002-4186-1435
Funding
No grant is acknowledged in the PubMed record.
6 · The paper itself
Abstract
Human plasma is a natural biomaterial that due to their protein composition is widely used for the development of clinical products, especially in the field of dermatology. In this context, this biomaterial has been used as a scaffold alone or combined with others for the development of cellular human plasma-based skin substitutes (HPSSs). Herein, the biological properties (cell viability, cell metabolic activity, protein secretion profile and histology) of several variations of a clinical HPSS model, regarding the biomaterial composition (alone or combined with six secondary biomaterials - serine, fibronectin, collagen, two types of laminins and hyaluronic acid), the cellular structure (trilayer, bilayer, monolayer and control without cells) and their skin tissue of origin (abdominal or foreskin cells) and the manufacturing process [effect of partial dehydration process in cell viability and comparison between submerged (SUB) and air/liquid interface (ALI) methodologies] have been evaluated and compared. Results reveal that the use of human plasma as a main biomaterial determines the
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Biological properties and characterization of several variations of a clinical human plasma-based skin substitute model and its manufacturing process. · full record | OpenQuestion